Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Non-Hodgkins Lymphoma
Conditions
B-Cell Non-Hodgkins Lymphoma
Trial Timeline
Mar 5, 2025 → Mar 30, 2029
NCT ID
NCT06806033About Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin
Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin is a phase 2 stage product being developed by Roche for B-Cell Non-Hodgkins Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06806033. Target conditions include B-Cell Non-Hodgkins Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06806033 | Phase 2 | Recruiting |
Competing Products
20 competing products in B-Cell Non-Hodgkins Lymphoma